Consensus OptimizeRx Corporation

Equities

OPRX

US68401U2042

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
10.42 ^USD	+2.16%		+13.76%	-27.18%

04-16	Earnings Flash (OPRX) OPTIMIZERX CORPORATION Posts Q4 Revenue $28.4M	MT
04-16	Earnings Flash (OPRX) OPTIMIZERX CORPORATION Posts Q4 EPS $0.26	MT

Evolution of the average Target Price on OptimizeRx Corporation

Price target over the last 5 years

History of analyst recommendation changes

91eeb99a9.yBqq9aj6ULvvkswVFEAaTKF2gOwrVMyWKIEAMS0vYT0.pyjnm_7XI8_Z25NxRDIiffcVuMEbYPzaGMtzAHJiNRCHKtOb5qogzYPgpw~b2a8b4e64326b3d2f1f8622d64d718dd

Analyst Recommendations on OptimizeRx Corporation

JMP Securities Initiates Coverage on OptimizeRx With Market Perform Rating, $15 Price Target	04-04	MT
RBC Adjusts OptimizeRx's Price Target to $17 From $14, Keeps Outperform Rating	01-10	MT
Barclays Starts OptimizeRx With Equalweight Rating, $15 Price Target	01-03	MT
Roth MKM Adjusts Price Target on OptimizeRx to $20 From $31, Maintains Buy Rating	15/08/23	MT
Lake street Adjusts OptimizeRx Price Target to $13 From $18, Maintains Buy Rating	15/08/23	MT
Stifel Adjusts Price Target on OptimizeRx to $13 From $16, Maintains Buy Rating	15/08/23	MT
B. Riley Cuts OptimizeRx's Price Target to $18 From $28 on Muted H2 Revenue Expectation, Keeps Buy Rating	15/08/23	MT
RBC Cuts Price Target on OptimizeRx to $14 From $18, Says 'Persisting Macro Headwinds Dampen' 2023 Outlook, Keeps Outperform Rating	15/08/23	MT
B. Riley Securities Lowers OptimizeRx's Price Target to $28 From $30 After 'Slight' Q4 Miss, Keeps Buy Rating	09/03/23	MT
RBC Cuts Price Target on OptimizeRx to $18 From $22 After 'Disappointing' 2023 Guidance; Outperform Rating Kept	09/03/23	MT
B. Riley Resumes OptimizeRx at Buy With $30 PT, Notes Increased Pharma Ad Spend on Digital Channels as Key Market Tailwind	02/02/23	MT
Stifel Starts OptimizeRx at Buy With $19 Price Target	01/11/22	MT
B. Riley Securities Lowers OptimizeRx's Price Target to $37 from $56 After Lower-than-Expected Q2 Results, Keeps Buy Rating	10/08/22	MT
SVB Securities Adjusts OptimizeRx's Price Target to $30 from $38, Keeps Outperform Rating	10/08/22	MT
RBC Cuts Price Target on OptimizeRx to $22 From $50, Maintains Outperform Rating	10/08/22	MT
Piper Sandler Adjusts Price Target on OptimizeRx to $16 From $29, Maintains Neutral Rating	10/08/22	MT
B. Riley Lowers OptimizeRx's Price Target to $56 from $71, Says Consensus Estimates at Risk of Moving Lower into Q2 Print; Keeps Buy Rating	20/07/22	MT
SVB Securities Initiates OptimizeRx at Outperform With $38 Price Target	15/07/22	MT
Piper Sandler Initiates Coverage on OptimizeRx With Neutral Rating, $29 Price Target	01/07/22	MT
RBC Capital Adjusts Price Target on OptimizeRx to $50 From $100, Maintains Outperform Rating	05/05/22	MT
Roth Capital Adjusts Price Target on OptimizeRx to $66 From $112, Reiterates Buy Rating	05/05/22	MT
B. Riley Lowers OptimizeRx's PT to $71 from $102, Notes Volatility, Rerating Across Public Markets, Early Q1 Omicron Impact; Keeps Buy Rating	02/05/22	MT
Lake Street Adjusts OptimizeRx Price Target to $76 From $98, Maintains Buy Rating	16/02/22	MT
RBC Boosts Price Target on OptimizeRx to $100 From $67, Says 'Commercial Momentum Remains Strong;' Outperform Kept	10/11/21	MT
OPTIMIZERX : B. Riley Resumes OptimizeRx at Buy with $102 PT, Says Addition to S&P 600, Management Hires, New Product Offerings Should Move Shares Higher	18/10/21	MT